UK markets open in 3 hours 50 minutes
  • NIKKEI 225

    28,665.96
    -90.90 (-0.32%)
     
  • HANG SENG

    29,453.11
    -474.65 (-1.59%)
     
  • CRUDE OIL

    52.42
    -0.71 (-1.34%)
     
  • GOLD FUTURES

    1,861.00
    -4.90 (-0.26%)
     
  • DOW

    31,176.01
    -12.39 (-0.04%)
     
  • BTC-GBP

    22,677.08
    +411.37 (+1.85%)
     
  • CMC Crypto 200

    616.17
    -63.74 (-9.37%)
     
  • ^IXIC

    13,530.92
    +73.67 (+0.55%)
     
  • ^FTAS

    3,802.30
    -14.01 (-0.37%)
     

Autolus Therapeutics to participate in Investor Conferences through January

Autolus Limited
·2-min read

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.

  • 11 January 2021 – The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company’s website at Autolus.

  • 13 January 2021 – The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the J.P. Morgan event and a live audio webcast will be available on the investor relations section of the Company’s website at Autolus.

Archived replays will be available for a period of 30 days after the conferences.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com